+Compare
ALPN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
559.42M

ALPN Alpine Immune Sciences Forecast, Technical & Fundamental Analysis

a developer of immunotherapeutics

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ALPN with price predictions
08:00 PM EDT Oct 02, 2023

ALPN in downward trend: 10-day moving average moved below 50-day moving average on September 14, 2023

The 10-day moving average for ALPN crossed bearishly below the 50-day moving average on September 14, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPN as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALPN moved below its 50-day moving average on September 19, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALPN entered a downward trend on October 03, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPN advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.303) is normal, around the industry mean (22.791). P/E Ratio (0.000) is within average values for comparable stocks, (131.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.084). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (16.474) is also within normal values, averaging (309.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 21%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 139% and the average quarterly volume growth was 150%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

ALPN is expected to report earnings to rise 25.93% to -34 cents per share on November 15

Alpine Immune Sciences ALPN Stock Earnings Reports
Q3'23
Est.
$-0.34
Q2'23
Beat
by $0.10
Q1'23
Beat
by $0.03
Q4'22
Missed
by $0.15
Q3'22
Missed
by $0.33
The last earnings report on August 14 showed earnings per share of -27 cents, beating the estimate of -37 cents. With 129.36K shares outstanding, the current market capitalization sits at 559.42M.
A.I. Advisor
published General Information

General Information

a developer of immunotherapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
188 East Blaine Street
Phone
+1 206 788-4545
Employees
126
Web
https://www.alpineimmunesciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWEIX8.37-0.03
-0.36%
American Century Equity Income Inv
OCLVX18.02-0.17
-0.93%
Optimum Large Cap Value C
CAREX12.57-0.21
-1.64%
Domini Sustainable Solutions Inv
VWYGX34.15-0.59
-1.70%
Voya Small Cap Growth C
LMIYX14.79-0.37
-2.44%
Lord Abbett Micro Cap Growth I

ALPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPN has been loosely correlated with CMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPN jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPN
1D Price
Change %
ALPN100%
+1.85%
CMRX - ALPN
40%
Loosely correlated
-2.32%
AXON - ALPN
39%
Loosely correlated
-2.09%
KYMR - ALPN
38%
Loosely correlated
+14.22%
VXRT - ALPN
38%
Loosely correlated
-3.80%
GLUE - ALPN
37%
Loosely correlated
-1.33%
More

Groups containing ALPN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPN
1D Price
Change %
ALPN100%
+1.85%
drugs
(undefined stocks)
41%
Loosely correlated
-1.36%
biotechnology
(undefined stocks)
35%
Loosely correlated
-1.11%
immunotherapy
(undefined stocks)
18%
Poorly correlated
+0.62%